1. Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX- Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.
- Author
-
Kim, B.-R., Yang, E.-K., Kim, D.-Y., Kim, S.-H., Moon, D.-C., Lee, J.-H., Kim, H.-J., and Lee, J.-C.
- Subjects
- *
ANTINEOPLASTIC agents , *IMMUNE response , *DENDRITIC cells , *CARBONIC anhydrase , *ACINETOBACTER baumannii , *CANCER treatment , *RENAL cell carcinoma , *MEMBRANE proteins , *GENE fusion - Abstract
Summary Carbonic anhydrase IX (CA9), a specific molecular marker for renal cell carcinoma (RCC), serves as a potential target for RCC-specific immunotherapy using dendritic cells (DCs). However, pulsing of DCs with CA9 alone is not sufficient for generation of a therapeutic anti-tumour immune response against RCC. In this study, in order to generate a potent anti-tumour immune response against RCC, we produced recombinant CA9- Acinetobacter baumannii outer membrane protein A (AbOmpA) fusion proteins, designated CA9-AbOmpA, and investigated the ability of DCs pulsed with CA9-AbOmpA fusion proteins in a murine renal cell carcinoma (RENCA) model. A recombinant CA9-AbOmpA fusion protein was composed of a unique proteoglycan-related region of CA9 (1-120 amino acids) fused at the C-terminus with transmembrane domain of AbOmpA (1-200 amino acids). This fusion protein was capable of inducing DC maturation and interleukin (IL)-12 production in DCs. Interaction of DCs pulsed with CA9-AbOmpA fusion proteins with naive T cells stimulated secretion of IL-2, interferon (IFN)-γ and tumour necrosis factor (TNF)-α in T cells. Lymphocytes harvested from mice immunized with DCs pulsed with CA9-AbOmpA fusion proteins secreted IFN-γ and showed a specific cytotoxic activity against CA9-expressing RENCA (RENCA-CA9) cells. Administration of CA9-AbOmpA-pulsed DC vaccine suppressed growth of RENCA-CA9 cells in mice with an established tumour burden. These results suggest that DCs pulsed with CA9-AbOmpA fusion proteins generate a specific anti-tumour immune response against RCC, which can be utilized in immunotherapy of RCC. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF